AzTrials
AzTrials

Non-small Cell Lung CancerPhase 2NCT06322108

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

A Phase 2 study testing Botensilimab + Balstilimab in people with Non-small Cell Lung Cancer, run by Immune Oncology Research Institute at 1 site in Armenia.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Non-small Cell Lung Cancer
What is being tested?
Botensilimab + Balstilimab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteArmenia
Study dates
13 Jun 2024to Apr 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically and IHC confirmed diagnosis of metastatic NSCLC which has not received any prior anticancer medicinal therapy for metastatic disease.
  • Negative for actionable EGFR mutations and ALK rearrangements.
  • Patients with recurrence after prior neoadjuvant or adjuvant chemotherapy or radiation therapy or immune checkpoint inhibitors for non-metastatic disease are eligible if recurrence occurred >6 months after the end of neoadjuvant or adjuvant treatment.
  • Documented informed consent of the participant and/or legally authorized representative
  • ≥ 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Show all 21Show fewer
  • Life expectancy ≥ 3 months.
  • Patients should have measurable metastatic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST guidelines.
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 7 days prior to day 1 of protocol therapy) (except subjects with Gilbert syndrome who must have a total bilirubin level of ≤3.0 × ULN).
  • Aspartate aminotransferase (AST) ≤ 2.5 x ULN, unless presence of liver metastases for which ≤ 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).
  • Alanine aminotransferase (ALT) ≤ 2.5 x ULN, unless presence of liver metastases for which ≤ 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).
  • Creatinine clearance ≥ 45 ml/min (within 7 days prior to day 1 of protocol therapy).
  • Alkaline phosphatase ≤ 3 x ULN (within 7 days prior to day 1 of protocol therapy).
  • Hemoglobin ≥ 9 g/dl (within 7 days prior to day 1 of protocol therapy).
  • Absolute neutrophil count (ANC) ≥ 1500/ul (within 7 days prior to day 1 of protocol therapy).
  • Platelets ≥ 100,000/mm^3 (within 7 days prior to day 1 of protocol therapy).
  • Albumin ≥ 3.0 g/dl (within 7 days prior to day 1 of protocol therapy).
  • Women of childbearing potential (WOCBP): negative serum pregnancy test (within 7 days prior to day 1 of protocol therapy)
  • Females of non-childbearing potential are defined as: i. ≥ 50 years of age and has not had menses for greater than 1 year ii. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation iii. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
  • Male and female patients of reproductive potential must use effective methods of contraception (defined in Appendix A) or abstain from sexual activity for the course of the study through at least 90 days after the last dose of balstilimab and/or botensilimab
  • Is willing and able to comply with the requirements of the protocol.

Who cannot join

  • Prior treatment with anti-CTLA-4 and anti-PD-(L)1 therapy. Note: Prior treatment with anti-PD-(L)1 therapy in the adjuvant setting is permitted if recurrence occurred >6 months after the end of adjuvant treatment.
  • Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Prior allogeneic organ transplantation.
  • Surgical intervention within 4 weeks prior to study treatment, except for minor procedures such as port placement.
  • Prior allergic reaction or hypersensitivity to any of the study drug components.
  • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment, i.e., with use of disease-modifying agents or immunosuppressive drugs.
Show all 24Show fewer
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), serious uncontrolled cardiac arrhythmia requiring medication.
  • QTcF (QTc interval corrected using Fridericia's formula) of > 480 ms.
  • Any persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] grade ≥ 2) from prior cancer therapy, excluding endocrinopathies stable on medication, stable neuropathy that is grade 2 or less, and alopecia.
  • Active brain metastases or leptomeningeal metastases with the following exceptions:
  • Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. Whole-brain radiation is not allowed. Subjects must have also discontinued steroid treatment 28 days prior to enrollment for the purpose of managing their brain metastases and they must be asymptomatic and radiologically stable ≥28 days before enrollment.
  • Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 730 days (or 2 years) prior to enrollment, i.e., subjects with a history of prior malignancy are eligible if treatment was completed at least 730 days (or 2 years) before enrollment and the subject has no evidence of disease. Subjects with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
  • Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.
  • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  • History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine or booster < 7 days before C1D1. For vaccines requiring more than 1 dose, the full series should be completed prior to C1D1, when feasible. Booster shot not required but also must be administered > 7 days from C1D1 or > 7 days from future cycle on study.
  • Uncontrolled infection with human Immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
  • Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Subjects who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 180 days prior to enrollment are eligible. Serological testing for HBV at screening is not required.
  • Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Subjects on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 180 days prior to enrollment. Serological testing for HCV at screening is not required.
  • Known active tuberculosis. Tuberculosis testing at screening is required.
  • Grade 3 or above neuropathy at the time of enrollment.
  • Dependence on total parenteral nutrition or intravenous hydration.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Trial locations and contacts

1 site in 1 country.

Armenia1 site

  • Hematology Center named after prof. R. Yeolyan

    Yerevan, 0014

Other trials in Armenia

About this study

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.

Read the detailed description

This is a single-arm, open-label phase II study to evaluate the safety and efficacy of the combination of botensilimab and balstilimab in participants with metastatic non-small cell lung cancer (NSCLC). The study will enroll participants with a histologically confirmed diagnosis of metastatic NSCLC and without targetable EGFR mutation or ALK rearrangement, while excluding those with untreated brain metastases or oligometastatic disease lacking targetable lesions.

The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods:

  • Screening Period: approximately 28 days
  • Treatment Period: up to 24 months, or until any criterion for stopping the study drug or withdrawal from the study occurs
  • Follow-up Period: up to 24 months from last dose of study treatment for every patient who is alive

Study Duration

  • Recruitment: 2 years
  • Treatment: 2 years
  • Follow-up: 2 years
Being tested
Botensilimab + Balstilimab
Keywords
Immunotherapy, Cancer, NSCLC
Medical subject headings
Carcinoma, Non-Small-Cell Lung, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Botensilimab + BalstilimabDrug

    Also called AGEN1181 + AGEN2034

    Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).

Study groups in NCT06322108
Study groupRoleWhat they receive
Botensilimab + BalstilimabExperimentalbotensilimab 75 mg IV every 6 weeks (up to 4 doses) + balstilimab 240 mg IV every 2 weeks
Receives: Drug: Botensilimab + Balstilimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 12-Month Progression-Free Survival (PFS)

    12-Month PFS is defined as the proportion of patients who remain alive and progression-free at 12 months from the first dose of investigational drug, where tumor progression is documented per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) as assessed by investigator.

    Measured: First dose to up to 12 months

Secondary outcomes (14)

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of subjects with a complete response (CR) or partial response (PR) per RECIST v1.1 and iRECIST, as assessed by investigator.

    Measured: First dose to up to 6 months

  2. Disease Control Rate (DCR)

    DCR is defined as the percentage of patients who have achieved complete response, partial response or stable disease per the RECIST v1.1 and iRECIST criteria.

    Measured: First dose to up to 6 months

  3. Duration of Response (DOR)

    DOR is defined as the time from initial objective radiographic response per RECIST v1.1 and iRECIST as assessed by investigator until the first documentation of progression or death, whichever occurs first.

    Measured: First dose to up to 48 months

  4. Time to Next Treatment (TTNT)

    TTNT is defined as the time from the first dose of investigational drug to the start date of a subsequent line of therapy.

    Measured: First dose to up to 48 months

  5. Overall Survival (OS) Time

    OS Time is defined as the time from the first dose of investigational drug until death to any cause.

    Measured: First dose to up to 48 months

  6. Frequency, severity, and duration of treatment emergent adverse events (TEAEs) (Safety and tolerability)

    Adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0), serious adverse events, AEs leading to treatment discontinuation or death.

    Measured: First dose to up to 27 months

  7. Health-related quality of life (HRQoL) according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    HRQoL is a patient-reported outcome (PRO) assessed using EORTC QLQ-C30.

    Measured: First dose to up to 25 months

  8. Health-related quality of life according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC29)

    Patient-reported outcome assessed using EORTC QLQ-LC29

    Measured: First dose to up to 25 months

  9. Health-related quality of life according to the 5 Level EuroQol 5 Dimension (EQ-5D-5L) questionnaire

    Patient-reported outcome assessed using EQ-5D-5L

    Measured: First dose to up to 25 months

  10. Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and 12-month progression-free survival

    PD-L1 expression at baseline will be assessed via immunohistochemistry and categorized into negative (<1%), low expression (1-49%), and high expression (>50%), and its correlation with 12-month progression-free survival will be investigated.

    Measured: First dose to up to 24 months

  11. Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and objective response rate

    PD-L1 expression at baseline will be assessed via immunohistochemistry and categorized into negative (<1%), low expression (1-49%), and high expression (>50%), and its correlation with objective response rate will be investigated.

    Measured: First dose to up to 24 months

  12. Correlation between existence of liver metastases on imaging at baseline and 12-month progression-free survival

    Presence of liver metastases at baseline will be assessed via imaging and its correlation with 12-month progression-free survival will be investigated.

    Measured: First dose to up to 24 months

  13. Correlation between existence of liver metastases on imaging at baseline and objective response rate

    Presence of liver metastases at baseline will be assessed via imaging and its correlation with objective response rate will be investigated.

    Measured: First dose to up to 24 months

  14. Level of circulating tumor DNA (ctDNA) at baseline and at different time points after start of treatment

    Level of ctDNA will be measured at screening, after start of treatment at 2 weeks, 4 weeks, 8 weeks, and at treatment discontinuation/disease progression.

    Measured: First dose to up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Mar 2024
  2. Study start13 Jun 2024
  3. Primary completionApr 2030 (estimated)
  4. Study completionApr 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06322108
Sponsor's protocol ID
IMMONC0008
Status last verified
Jun 2026
First submitted
28 Feb 2024
Last updated
8 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Botensilimab + Balstilimab in people with Non-small Cell Lung Cancer, run by Immune Oncology Research Institute at 1 site in Armenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Armenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

12-Month Progression-Free Survival (PFS) (time frame: First dose to up to 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06322108.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06322108 | AzTrials